Table 1 Baseline and Tumor characteristics of uterine sarcoma patients stratified on the histological type (n = 40)

Age in years (median, IQR)

49 (40–55.5)

43 (39.5- 52)

53.5 (48–58)

42.5 (37.5–55.5)

56.5 (45–70)

 < 0.001*

Marital status, n(%)

 Single

5 (12.50)

4 (80.0)

0 (0.0)

0 (0.0)

1 (20.0)

0.175

 Married

35 (87.50)

12 (34.29)

10 (28.57)

8 (22.86)

5 (14.29)

Family History of cancer, n(%)

 Yes

2 (5.0)

1 (50.0)

0 (100.0)

0 (100.0)

1 (50.0)

0.437

 No

38 (95.0)

15 (39.47)

10 (26.32)

8 (21.05)

5 (13.16)

Medical illness, n(%)

 DM

10 (25.0)

1 (10.0)

4 (40.0)

2 (20.0)

3 (30.0)

0.176

 HTN

8 (20.0)

5 (62.50)

2 (25.00)

0 (0.0)

1 (1.0)

 None

22 (55.0)

10 (45.45)

4 (18.18)

6 (27.27)

2 (9.09)

Menstrual status, n(%)

 Premenopausal

17 (42.50)

8 (47.06)

1 (5.88)

6 (35.29)

2 (11.76)

0.039

 Postmenopausal

23 (57.50)

8 (34.78)

9 (39.13)

2 (8.70)

4 (17.39)

Parity, n(%)

 Parity = 0

3 (8.57)

0 (0.0)

0 (0.0)

3 (42.86)

0 (0.0)

0.004

 Parity ≥ 1

37 (91.43)

14 (43.75)

9 (28.13)

4 (12.50)

4 (15.63)

Pre-op endometrial biopsy, n(%)

 Positive

13 (32.50)

4 (30.77)

4 (30.77)

2 (15.38)

3 (23.08)

0.534

 Negative

1 (2.50)

0 (0.0)

1 (100.0)

0 (0.0)

0 (0.0)

 Not performed / Not documented

26 (65.0)

12 (46.15)

5 (19.23)

6 (23.08)

3 (11.54)

FIGO Stage, n(%)

 I

16 (40.0)

9 (56.25)

4 (25.0)

2 (12.50)

1 (6.25)

 II

8 (20.0)

1 (12.50)

4 (50.0)

3 (37.50)

0 (0.0)

0.034

 III

5 (12.50)

1 (20.0)

0 (0.0)

1 (20.0)

3 (60.0)

 IV

3 (7.50)

3 (100.0)

0 (0.0)

0 (0.0)

0 (0.0)

 Missing/Incomplete data

8 (20.0)

2 (25.0)

2 (25.0)

2 (25.0)

2 (25.0)

Histological Grade, n(%)

 Well-differentiated

6 (27.27)

4 (66.67)

1 (16.67)

1 (16.67)

0 (0.0)

0.090

 Moderately-differentiated

4 (18.18)

0 (0.0)

1 (25.0)

2 (50.0)

1 (25.0)

 Poor differentiated

12 (54.55)

4 (33.33)

4 (33.33)

0 (0.0)

4 (33.33)

Tumor size (cm),

 < 5 cm

13 (34.21)

4 (30.77)

2 (15.38)

5 (38.46)

2 (15.38)

0.577

 ≥ 5 cm

19 (50.0)

9 (47.37)

6 (31.58)

2 (10.53)

2 (10.53)

Myometrial Invasion, n(%)

 Negative

2 (5.26)

0 (0.0)

0 (0.0)

1 (50.0)

1 (50.0)

0.221

 Positive (< / ≥ 50%)

36 (94.74)

16 (44.44)

9 (25.0)

7 (19.44)

4 (11.11)

Mitotic index, n (%)

 < 15 per HPF

19 (63.33)

5 (26.32)

5 (26.32)

7 (36.84)

2 (10.53)

0.047

 > 15 per HPF

11 (36.67)

8 (72.73)

2 (18.18)

0 (0.0)

1 (9.09)

LVI, n (%)

 Positive

23 (67.65)

9 (39.13)

9 (39.13)

3 (13.04)

2 (8.70)

0.042

 Negative

11 (32.35)

4 (36.36)

0 (0.0)

5 (45.45)

2 (18.18)

Lymph Node status, n (%)

 Positive

15 (40.54)

3 (20.0)

5 (33.33)

4 (26.67)

3 (20.0)

0.032

 Negative

22 (59.46)

13 (59.09)

4 (18.18)

4 (18.18)

1 (4.55)

Pelvic wash, n(%)

 Positive

4 (10.81)

2 (50.0)

2 (50.0)

0 (0.0)

0 (0.0)

0.437

 Negative

33 (89.19)

14 (42.42)

7 (21.21)

8 (24.24)

4 (12.12)